TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6117260
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg aspirin administered 12 hours before operation
Study: 30959146
Drug: Adjusted medication
Normalized name: DEPEND ADJUSTABLE,MAXIMUM SM/MED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted medication protocol
Study: 30959146
Drug: Fixed medication
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed medication protocol
Study: 28381416
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg/day for 21 days of a 28-day cycle)
Study: 16875928
Drug: Fosinopril (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (low dosage)
Study: 16875928
Drug: Fosinopril (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (high dosage)
Study: 12629054
Drug: Fluconazole (Fluzole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (Fluzole 100 mg/day) starting from the sixth irradiation session throughout the treatment
Study: 12629054
Drug: Fluconazole (Fluzole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (Fluzole 100 mg/day)
Study: 9311220
Drug: Intravenous neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neostigmine (2 ml, 1 mg)
Study: 9311220
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 ml, 0.5 mg) and neostigmine (2 ml, 1 mg)
Study: 23011423
Drug: Microcurrent reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent reflexology sessions and cortexin treatment (10 mg, 10 injections)
Study: 23011423
Drug: Reflexology treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatments only
Study: 15737667
Drug: Tryptophan-free mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan-free mixture (31.2 g of amino acids)
Study: 15737667
Drug: Control mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control mixture (33.2 g of amino acids)
Study: 14523211
Drug: Chlorhexidine (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (4% detergent water solution)
Study: 4008115
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg theophylline
Study: 2071262
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg theophylline followed by 400 mg rufloxacin after 30 min
Study: 2071262
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine followed by 400 mg rufloxacin after 30 min
Study: 6357692
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (Bay K 9320) 20 mg, three times daily for three weeks
Study: 6357692
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (Bay K 9320)
Study: 31995024
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg for three months
Study: 31995024
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy subgroup with Esomeprazole
Study: 19669019
Drug: Supplementary oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary oxygen administration
Study: 17438407
Drug: Sarpogrelate hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate hydrochloride 100 mg 3 times per day orally for 12 weeks
Study: 11181869
Drug: GKI infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GKI infusion (500 ml 10% glucose, 20 mmol potassium chloride, 16 units of insulin)
Study: 11181869
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy with 154 mmol/l (0.9%) saline at 100 ml/h for 24 hours
Study: 10211539
Drug: Sparfloxacin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg daily for 9 days
Study: 2620532
Drug: Cervagem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervagem (1 mg vaginal suppository for 4 hours)
Study: 29605624
Drug: Tiotropium-olodaterol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium-olodaterol 5 μg-5 μg once daily
Study: 29605624
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg once daily
Study: 22610452
Drug: 7% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% hypertonic saline, nebulized twice daily for 48 weeks
Study: 22610452
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline, nebulized twice daily for 48 weeks
Study: 20415801
Drug: Xylitol rinse
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol rinse (20 mL of an aqueous solution of xylitol twice daily for 60 seconds, dose: 4.4 g/day)
Study: 20415801
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (two xylitol gum pellets for at least 5 minutes three times daily, dose: 4.3g/day)
Study: 18710748
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist therapy (2, 6-month cycles)
Study: 18710748
Drug: Prior local
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior local radiation therapy
Study: 15933273
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADLs) dependence
Study: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray 1 mg
Study: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray 0.5 mg
Study: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray (both doses)
Study: 11398305
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray
Study: 2464912
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg per day for 4 weeks)
Study: 2186673
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 200 micrograms bid
Study: 31659612
Drug: Serum AFP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum AFP ≥ 100 ng/ml
Study: 28496190
Drug: Combination budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination budesonide/formoterol inhaler (single maintenance and reliever therapy)
Study: 28496190
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose budesonide/formoterol with salbutamol as reliever (Standard regimen)
Study: 9797591
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (intervention group)
Study: 8054915
Drug: IFN‐alpha 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha 2a at a dose of 1 x 10(6) units/day sc for 28 days with CYA
Study: 8054915
Drug: IFN‐alpha 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha 2a at a dose of 3 x 10(6) units/day sc for 28 days with CYA
Study: 19515371
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation (DC)
Study: 27027634
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg grapiprant suspension
Study: 27027634
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg grapiprant suspension
Study: 27027634
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg grapiprant tablet
Study: 27027634
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg grapiprant tablet
Study: 16106334
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT) for 8 sessions over 8 weeks
Study: 11828293
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g every 12 hours)
Study: 11828293
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g every 8 hours)
Study: 9895384
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amino acids (LDA)
Study: 9895384
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose amino acids (HDA)
Study: 153863
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day of Ro 10‐9359
Study: 153863
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice every week of Ro 10‐9359
Study: 31553835
Drug: Quintupling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quintupling the dose of fluticasone (to 250 μg twice a day)
Study: 31553835
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the fluticasone (to 100 μg twice a day) and adding salmeterol (50 μg twice a day)
Study: 31553835
Drug: Salmeterol (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (low-dose fluticasone)
Study: 31553835
Drug: Salmeterol (medium-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (medium-dose fluticasone)
Study: 26945216
Drug: Interferential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential Therapy (IFT) with standard care
Study: 20697200
Drug: Hib(2.5 µg)‐MenC(5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib(2.5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Study: 20697200
Drug: Hib(5 µg)‐MenC(10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib(5 µg)‐MenC(10 µg)‐MenY(10 µg)‐TT co-administered with DTPa‐HBV‐IPV
Study: 20697200
Drug: Hib(5 µg)‐MenC(5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib(5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Study: 20697200
Drug: Hib(5 µg)‐MenC(5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib(5 µg)‐MenC(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Study: 20697200
Drug: Licensed conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed conjugate MenC‐CRM197 vaccine co-administered with DTPa‐HBV‐IPV/Hib
Study: 20697200
Drug: HibMenCY and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HibMenCY and HibMenC conjugate vaccines
Study: 1525095
Drug: Active policy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active policy (immediate oxytocin infusion)
Study: 3839262
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with periodic BCVP reinduction
Study: 31155161
Drug: MOSAIC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOSAIC treatment (two 60-minute home-based sessions and two 20-minute booster telephone calls incorporating behavior-change techniques)
Study: 27103215
Drug: Dilemma-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilemma-focused therapy (DFT)
Study: 24662855
Drug: TEG-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEG-guided dosing (50 mg twice a day)
Study: 24662855
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (30 mg twice a day)
Study: 20962021
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus lifestyle program of weight management
Study: 19564296
Drug: Electronic health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic health record-based clinical alerts for influenza vaccine at intervention sites
Study: 17309130
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels in SLE patients
Study: 7727578
Drug: No antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiretroviral treatment (No Rx)
Study: 2035339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medicamentous therapy and percutaneous drainage
Study: 28704587
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 50, 125, 300 or 600 mg weekly
Study: 28704587
Drug: Dutasteride 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 2.5 mg daily
Study: 17968938
Drug: Quinapril 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 80 mg/day
Study: 19121433
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DESs)
Study: 11802510
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g t.d.s. for 4 weeks (SAC group; n = 60)
Study: 11802510
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.d. for the first 7 days and 40 mg o.d. for the next 3 weeks (PAC group; n = 60)
Study: 7449642
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment with prednisolone and azathioprine
Study: 7449642
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunosuppressive treatment)
Study: 27588568
Drug: Liposomal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal iron 28 mg (LI28)
Study: 27588568
Drug: Liposomal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal iron 14 mg (LI14)
Study: 27588568
Drug: Ferrous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous iron 30 mg (FI)
Study: 24106757
Drug: 0.05% S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% S. flavescens extract cream
Study: 18761603
Drug: Peg‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2a monotherapy (n = 59)
Study: 18761603
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n = 61)
Study: 18761603
Drug: Peg‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2a monotherapy with low viraemia (≤300,000 IU/mL)
Study: 18761603
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with low viraemia (≤300,000 IU/mL)
Study: 18761603
Drug: Peg‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2a monotherapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Study: 18761603
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Study: 18761603
Drug: Peg‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN alpha‐2a monotherapy with high viraemia (>700,000 IU/mL)
Study: 18761603
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with high viraemia (>700,000 IU/mL)
Study: 11468498
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care program supervised by a psychiatrist and a primary care expert, providing intervention services for 12 months using antidepressant medications and Problem Solving Treatment in Primary Care.
Study: 9503770
Drug: Topical anesthetics
Normalized name: topical anesthetics (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics (various types including vapocoolants, needleless injection systems, iontophoresis, EMLA Cream)
Study: 8061739
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (enteral administration of a balanced glucose-electrolyte solution)
Study: 8061739
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solutions with additional benefits
Study: 3361903
Drug: Alcohol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (dose not specified)
Study: 28186711
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose statin exposure (EM 1)
Study: 28186711
Drug: Cumulative standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative standardized statin dose at index date (EM 2)
Study: 28186711
Drug: Cumulative standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative standardized statin dose in the 180 days prior to index date (EM 3)
Study: 21239518
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg once daily for 13 days)
Study: 8741955
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day nicotine skin patch for smokers
Study: 8741955
Drug: 7 mg/day
Normalized name: nicotine 7 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg/day nicotine skin patch for nonsmokers
Study: 8741955
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patch (both dosages)
Study: 8741955
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patch (smokers only)
Study: 12491501
Drug: L-PAM (L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PAM (L-phenylalanine mustard)
Study: 3917352
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with TM followed by CAF upon failure
Study: 3917352
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with TM
Study: 1105174
Drug: L-PAM
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM
Study: 28661062
Drug: Haemoglobin trigger
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin trigger for RBCT < 9.7 g dL-1 (arm A)
Study: 28661062
Drug: Haemoglobin trigger
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin trigger for RBCT < lower normal level (female: 11.5 g dL-1, male: 13.1 g dL-1) (arm B)
Study: 21048970
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus amodiaquine (AS+AQ) monthly
Study: 12383808
Drug: Topical 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5‐fluorouracil (50 mg/ml for 5 minutes)
Study: 12383808
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (0.2 mg/ml for 2 minutes)
Study: 10440143
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (1 g/day for 2 days)
Study: 7580056
Drug: Bushen Jiangu
Normalized name: Jiang Huang (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Jiangu (BSJG) capsule
Study: 3308737
Drug: Calcium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium treatment
Study: 2181310
Drug: Melphalan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan (0.2 mg per kilogram of body weight per day for five days, repeated every four to six weeks for up to 12 cycles)
Study: 28946522
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MG)
Study: 25663642
Drug: Daily antioxidant
Normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antioxidant therapy
Study: 25663642
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy in chronic ITP
Study: 21292056
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation (BA) therapy consisting of eight 30- to 60-minute sessions across 4 weeks
Study: 15390011
Drug: Levetiracetam (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (titrated to 3,000 mg/day or lower maximal tolerated dose)
Study: 11243949
Drug: Methylprednisolone (MP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (MP), 0.5 mg/kg q6h for 3 days
Study: 11243949
Drug: Methylprednisolone (MP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (MP), 0.5 mg/kg q6h for 3 days, then tapered and terminated on the tenth day
Study: 11243949
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3-day MP treatment)
Study: 11243949
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10-day MP treatment)
Study: 9683004
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g oral dosage of glucose